相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。A randomized phase 3 study on the effect of thalidomide combined with adriamycin, dexamethasone, and high-dose melphalan, followed by thalidomide maintenance in patients with multiple myeloma
Henk M. Lokhorst et al.
BLOOD (2010)
Lenalidomide as salvage therapy after allo-SCT for multiple myeloma is effective and leads to an increase of activated NK (NKp44+) and T (HLA-DR+) cells
M. Lioznov et al.
BONE MARROW TRANSPLANTATION (2010)
Unrelated stem cell transplantation after reduced intensity conditioning for patients with multiple myeloma relapsing after autologous transplantation
Nicolaus Kroeger et al.
BRITISH JOURNAL OF HAEMATOLOGY (2010)
Patterns of Improved Survival in Patients With Multiple Myeloma in the Twenty-First Century: A Population-Based Study
Ingemar Turesson et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Allogeneic Hematopoietic Stem-Cell Transplantation for Patients 50 Years or Older With Myelodysplastic Syndromes or Secondary Acute Myeloid Leukemia
ZiYi Lim et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
A Phase II Trial of Autologous Stem Cell Transplantation Followed by Mini-Allogeneic Stem Cell Transplantation for the Treatment of Multiple Myeloma: An Analysis of Eastern Cooperative Oncology Group ECOG E4A98 and E1A97
David H. Vesole et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2009)
Nonmyeloablative allografting for newly diagnosed multiple myeloma: the experience of the Gruppo Italiano Trapianti di Midollo
Benedetto Bruno et al.
BLOOD (2009)
Long-term outcome of patients with multiple myeloma after autologous hematopoietic cell transplantation and nonmyeloablative allografting
Marcello Rotta et al.
BLOOD (2009)
Bortezomib, tacrolimus, and methotrexate for prophylaxis of graft-versus-host disease after reduced-intensity conditioning allogeneic stem cell transplantation from HLA-mismatched unrelated donors
John Koreth et al.
BLOOD (2009)
Mobilization in myeloma revisited: IMWG consensus perspectives on stem cell collection following initial therapy with thalidomide-, lenalidomide-, or bortezomib-containing regimens
Shaji Kumar et al.
BLOOD (2009)
CD8+ T-cell responses to tumor-associated antigens correlate with superior relapse-free survival after allo-SCT
M. Kapp et al.
BONE MARROW TRANSPLANTATION (2009)
Rapid Identification of Clinical Relevant Minor Histocompatibility Antigens via Genome-Wide Zygosity-Genotype Correlation Analysis
Robbert M. Spaapen et al.
CLINICAL CANCER RESEARCH (2009)
Post-transplant immunotherapy with donor-lymphocyte infusion and novel agents to upgrade partial into complete and molecular remission in allografted patients with multiple myeloma
Nicolaus Kroeger et al.
EXPERIMENTAL HEMATOLOGY (2009)
Treatment with bortezomib of human CD4+ T cells preserves natural regulatory T cells and allows the emergence of a distinct suppressor T-cell population
Belen Blanco et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2009)
Short-Term Thalidomide Incorporated Into Double Autologous Stem-Cell Transplantation Improves Outcomes in Comparison With Double Autotransplantation for Multiple Myeloma
Michele Cavo et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Consolidation Therapy With Low-Dose Thalidomide and Prednisolone Prolongs the Survival of Multiple Myeloma Patients Undergoing a Single Autologous Stem-Cell Transplantation Procedure
Andrew Spencer et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Lenalidomide alone or in combination with dexamethasone is highly effective in patients with relapsed multiple myeloma following allogeneic stem cell transplantation and increases the frequency of CD4(+)Foxp3(+) T cells
M. C. Minnema et al.
LEUKEMIA (2009)
Targeting haematopoietic-specific minor histocompatibility antigens to distinguish graft-versus-tumour effects from graft-versus-host disease
Robbert Spaapen et al.
BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY (2008)
Comparison of twin and autologous transplants for multiple myeloma
Asad Bashey et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2008)
Long-term follow-up results of IFM99-03 and IFM99-04 trials comparing nonmyeloablative allotransplantation with autologous transplantation in high-risk de novo multiple myeloma
Philippe Moreau et al.
BLOOD (2008)
A prospective PETHEMA study of tandem autologous transplantation versus autograft followed by reduced-intensity conditioning allogeneic transplantation in newly diagnosed multiple myeloma
Laura Rosinol et al.
BLOOD (2008)
Sustained complete remissions in multiple myeloma linked to bortezomib in total therapy 3: comparison with total therapy 2
Mauricio Pineda-Roman et al.
BRITISH JOURNAL OF HAEMATOLOGY (2008)
Generation of Antitumor Invariant Natural Killer T Cell Lines in Multiple Myeloma and Promotion of Their Functions via Lenalidomide: A Strategy for Immunotherapy
Weihua Song et al.
CLINICAL CANCER RESEARCH (2008)
High response rate and improved graft-versus-host disease following bortezomib as salvage therapy after reduced intensity conditioning allogeneic stem cell transplantation for multiple myeloma
Jean El-Cheikh et al.
HAEMATOLOGICA (2008)
Toward targeting B cell cancers with CD4+ CTLs: identification of a CD19-encoded minor histocompatibility antigen using a novel genome-wide analysis
Robbert M. Spaapen et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2008)
Impact of genetic abnormalities on survival after allogeneic hematopoietic stem cell transplantation in multiple myeloma
G. Schilling et al.
LEUKEMIA (2008)
Improved survival in multiple myeloma and the impact of novel therapies
Shaji K. Kumar et al.
BLOOD (2008)
Anti-myeloma activity of endogenous and adoptively transferred activated natural killer cells in experimental multiple myeloma model
Evren Alici et al.
EXPERIMENTAL HEMATOLOGY (2007)
Relapse risk after autologous transplantation in patients with newly diagnosed myeloma is not related with infused tumor cell load and the outcome is not improved by CD34+cell selection: long term follow-up of an EBMT phase III randomized study
Jean-Henri Bourhis et al.
HAEMATOLOGICA (2007)
Incorporating bortezomib into upfront treatment for multiple myeloma: early results of total therapy 3
Bart Barlogie et al.
BRITISH JOURNAL OF HAEMATOLOGY (2007)
Risk assessment in haematopoietic stem cell transplantation: Impact of donor-recipient sex combination in allogeneic transplantation
Gosta Gahrton
BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY (2007)
Multiple myeloma-reactive T cells recognize an activation-induced minor histocompatibility antigen encoded by the ATP-dependent interferon-responsive (ADIR) gene
Cornelis A. M. van Bergen et al.
BLOOD (2007)
Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myelome
Herve Avet-Loiseau et al.
BLOOD (2007)
Reduced-intensity conditioning for myeloma:: lower nonrelapse mortality but higher relapse rates compared with myeloablative conditioning
Charles Crawley et al.
BLOOD (2007)
Facilitating matched pairing and expression of TCR chains introduced into human T cells
Jurgen Kuball et al.
BLOOD (2007)
A comparison of allografting with autografting for newly diagnosed myeloma
Benedetto Bruno et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Gene expression profiling of B lymphocytes and plasma cells from Waldenstrom's macroglobulinemia:: comparison with expression patterns of the same cell counterparts from chronic lymphocytic leukemia, multiple myeloma and normal individuals
N. C. Gutierrez et al.
LEUKEMIA (2007)
Cancer-testis antigens are commonly expressed in multiple myeloma and induce systemic immunity following allogeneic stem cell transplantation
Djordje Atanackovic et al.
BLOOD (2007)
Use of bortezomib in the management of chronic graft-versus-host disease among multiple myeloma patients relapsing after allogeneic transplantation
Juan Mateos-Mazon et al.
HAEMATOLOGICA (2007)
Reduced intensity conditioning with thiotepa, fludarabine, and melphalan is effective in advanced multiple myeloma
Ignazio Majolino et al.
LEUKEMIA & LYMPHOMA (2007)
Maintenance, therapy with thalidomide improves survival in patients with multiple myeloma
Michel Attal et al.
BLOOD (2006)
Factors associated with outcomes in allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning after failed myeloablative hematopoietic cell transplantation
Frederic Baron et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Bortezomib after dose-reduced allogeneic stem cell transplantation for multiple myeloma to enhance or maintain remission status
Nicolaus Kroeger et al.
EXPERIMENTAL HEMATOLOGY (2006)
Bortezomib induces selective depletion of alloreactive T lymphocytes and decreases the production of Th1 cytokines
B Blanco et al.
BLOOD (2006)
Prospective comparison of autologous stem cell transplantation followed by dose-reduced allograft (IFM99-03 trial) with tandem autologous stem cell transplantation (IFM99-04 trial) in high-risk de novo multiple myeloma
F Garban et al.
BLOOD (2006)
Remarkable activity of novel agents bortezomib and thalidomide in patients not responding to donor lymphocyte infusions following nonmyeloablative allogeneic stem cell transplantation in multiple myeloma
NWCJ van de Donk et al.
BLOOD (2006)
Thalidomide and hematopoietic-cell transplantation for multiple myeloma
B Barlogie et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: Final results of phase III US intergroup trial S9321
B Barlogie et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
NF-κB as a target for the prevention of graft-versus-host disease:: comparative efficacy of bortezomib and PS-1145
S Vodanovic-Jankovic et al.
BLOOD (2006)
Combined vaccination with idiotype-pulsed allogeneic dendritic cells and soluble protein idiotype for multiple myeloma patients relapsing after reduced-intensity conditioning allogeneic stem cell transplantation
M Bendandi et al.
LEUKEMIA & LYMPHOMA (2006)
Prognostic factors for donor lymphocyte infusions following non-myeloablative allogeneic stem cell transplantation in multiple myeloma
N. W. C. J. van de Donk et al.
BONE MARROW TRANSPLANTATION (2006)
HLA class II restricted T-cell receptor gene transfer generates CD4+ T cells with helper activity as well as cytotoxic capacity
LT van der Veken et al.
GENE THERAPY (2005)
Long-term outcome of nonmyeloablative allogeneic transplantation in patients with high-risk multiple myeloma
S Gerull et al.
BONE MARROW TRANSPLANTATION (2005)
Differential effects of proteasome inhibition by bortezomib on murine acute graft-versus-host disease (GVHD): delayed administration of bortezomib results in increased GVHD-dependent gastrointestinal toxicity
K Sun et al.
BLOOD (2005)
Clinical implications of t(11;14)(q13;q32), t(4;14)(p16.3;q32), and-17p13 in myeloma patients treated with high-dose therapy
MA Gertz et al.
BLOOD (2005)
Tumor antigen immunization of sibling stem cell transplant donors in multiple myeloma
S Neelapu et al.
BONE MARROW TRANSPLANTATION (2005)
Outcomes for reduced-intensity allogeneic transplantation for multiple myeloma:: an analysis of prognostic factors from the Chronic Leukaemia Working Party of the EBMT
C Crawley et al.
BLOOD (2005)
The impact of donor gender on outcome of allogeneic hematopoietic stem cell transplantation for multiple myeloma:: reduced relapse risk in female to male transplants
G Gahrton et al.
BONE MARROW TRANSPLANTATION (2005)
p53 gene deletion detected by fluorescence in situ hybridization is an adverse prognostic factor for patients with multiple myeloma following autologous stem cell transplantation
H Chang et al.
BLOOD (2005)
Susceptibility of malignant plasma cells to HA-1H specific lysis suggests a role for the minor histocompatibility antigen HA-1 in the graft-versus-myeloma effect
PA Holloway et al.
LEUKEMIA (2004)
Donor lymphocyte infusions for multiple myeloma: clinical results and novel perspectives
R Zeiser et al.
BONE MARROW TRANSPLANTATION (2004)
Graft-versus-myeloma effect following antithymocyte globulin-based reduced intensity conditioning allogeneic stem cell transplantation
M Mohty et al.
BONE MARROW TRANSPLANTATION (2004)
Low-dose thalidomide and donor lymphocyte infusion as adoptive immunotherapy after allogeneic stem cell transplantation in patients with multiple myeloma
N Kröger et al.
BLOOD (2004)
The occurrence of graft-versus-host disease is the major predictive factor for response to donor lymphocyte infusions in multiple myeloma
HM Lokhorst et al.
BLOOD (2004)
Deletion of chromosome band 13q14 as detected by fluorescence in situ hybridization is a prognostic factor in patients with multiple myeloma who are receiving allogeneic dose-reduced stem cell transplantation
N Kröger et al.
BLOOD (2004)
Inhibition of acute graft-versus-host disease with retention of graft-versus-tumor effects by the proteasome inhibitor bortezomib
K Sun et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2004)
Relapse to prior autograft and chronic graft-versus-host disease are the strongest prognostic factors for outcome of melphalan/fludarabine-based dose-reduced allogeneic stem cell transplantation in patients with multiple myeloma
N Kröger et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2004)
Redirection of antileukemic reactivity of peripheral T lymphocytes using gene transfer of minor histocompatibility antigen HA-2-specific T-cell receptor complexes expressing a conserved alpha joining region
MHM Heemskerk et al.
BLOOD (2003)
Molecular remission after myeloablative allogeneic stem cell transplantation predicts a better relapse-free survival in patients with multiple myeloma
P Corradini et al.
BLOOD (2003)
Clinical and biologic implications of recurrent genomic aberrations in myeloma
R Fonseca et al.
BLOOD (2003)
Partially T-Cell-depleted allogeneic stem-cell transplantation for first-line treatment of multiple myeloma: A prospective evaluation of patients treated in the phase III study HOVON 24 MM
HM Lokhorst et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Follow-up of patients with progressive multiple myeloma undergoing allografts after reduced-intensity conditioning
H Einsele et al.
BRITISH JOURNAL OF HAEMATOLOGY (2003)
Peripheral blood stem cell contamination evaluated by a highly sensitive molecular method fails to predict outcome of autotransplanted multiple myeloma patients
S Galimberti et al.
BRITISH JOURNAL OF HAEMATOLOGY (2003)
Prognostic factors in allogeneic transplantation for patients with high-risk multiple myeloma after reduced intensity conditioning
CK Lee et al.
EXPERIMENTAL HEMATOLOGY (2003)
Allografting with nonmyeloablative conditioning following cytoreductive autografts for the treatment of patients with multiple myeloma
DG Maloney et al.
BLOOD (2003)
Dual-specific T cells combine proliferation and antitumor activity
MH Kershaw et al.
NATURE BIOTECHNOLOGY (2002)
Autologous stem cell transplantation followed by a dose-reduced allograft induces high complete remission rate in multiple myeloma
N Kröger et al.
BLOOD (2002)
Oncogenesis of multiple myeloma: 14q32 and 13q chromosomal abnormalities are not randomly distributed, but correlate with natural history, immunological features, and clinical presentation
H Avet-Loiseau et al.
BLOOD (2002)
Negative selection of peripheral blood stem cells to support a tandem autologous transplantation programme in multiple myeloma
AM Barbui et al.
BRITISH JOURNAL OF HAEMATOLOGY (2002)
Circumventing tolerance to a human MDM2-derived tumor antigen by TCR gene transfer
T Stanislawski et al.
NATURE IMMUNOLOGY (2001)
Purging of autologous peripheral-blood stem cells using CD34 selection does not improve overall or progression-free survival after high-dose chemotherapy for multiple myeloma: Results of a multicenter randomized controlled trial
AK Stewart et al.
JOURNAL OF CLINICAL ONCOLOGY (2001)
Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects
PA McSweeney et al.
BLOOD (2001)
Progress in allogeneic bone marrow and peripheral blood stem cell transplantation for multiple myeloma:: a comparison between transplants performed 1983-93 and 1994-98 at European Group for Blood and Marrow Transplantation centres
G Gahrton et al.
BRITISH JOURNAL OF HAEMATOLOGY (2001)
Chromosome 13 abnormalities identified by FISH analysis and serum β2-microglobulin produce a powerful myeloma staging system for patients receiving high-dose therapy
T Facon et al.
BLOOD (2001)
Grafting primary human T lymphocytes with cancer-specific chimeric single chain and two chain TCR
RA Willemsen et al.
GENE THERAPY (2000)
Donor lymphocyte infusions for relapsed multiple myeloma after allogeneic stem-cell transplantation: Predictive factors for response and long-term outcome
HM Lokhorst et al.
JOURNAL OF CLINICAL ONCOLOGY (2000)
Functional reconstitution of class II MHC-Restricted T cell immunity mediated by retroviral transfer of the αβ TCR complex
K Fujio et al.
JOURNAL OF IMMUNOLOGY (2000)
分享论文
